Roblitinib is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4), used as an active pharmaceutical ingredient. It selectively and reversibly binds to FGFR4, inhibiting its activity in cancer cells that overexpress this receptor.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1708971-55-4
Oritavancin
pharmaceutical raw material
4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
pharmaceutical raw material
3-Amino-5-acetamido-2,4,6-triiodobenzoate
pharmaceutical raw material
Exatecan
pharmaceutical raw material
N-[5-cyano-4-(2-methoxyethylamino)-2-pyridinyl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide
BHKDKKZMPODMIQ-UHFFFAOYSA-N
CN1CCN(C(=O)C1)CC2=C(N=C3C(=C2)CCCN3C(=O)NC4=NC=C(C(=C4)NCCOC)C#N)C=O